T

TiumBio Co Ltd
KOSDAQ:321550

Watchlist Manager
TiumBio Co Ltd
KOSDAQ:321550
Watchlist
Price: 6 030 KRW -2.43% Market Closed
Market Cap: 166.9B KRW

TiumBio Co Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

TiumBio Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
T
TiumBio Co Ltd
KOSDAQ:321550
Net Income (Common)
-â‚©20.6B
CAGR 3-Years
13%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Income (Common)
â‚©737.8B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
20%
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Income (Common)
â‚©127B
CAGR 3-Years
44%
CAGR 5-Years
41%
CAGR 10-Years
28%
Alteogen Inc
KOSDAQ:196170
Net Income (Common)
â‚©94.3B
CAGR 3-Years
249%
CAGR 5-Years
60%
CAGR 10-Years
77%
A
ABL Bio Inc
KOSDAQ:298380
Net Income (Common)
-â‚©20.5B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
D
DND PharmaTech Inc
KOSDAQ:347850
Net Income (Common)
-â‚©28.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TiumBio Co Ltd
Glance View

Market Cap
163B KRW
Industry
Biotechnology

TiumBio Co., Ltd. engages in the development and manufacture of therapeutic drugs. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2019-11-22. The firm researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.

Intrinsic Value
3 279.79 KRW
Overvaluation 46%
Intrinsic Value
Price
T

See Also

What is TiumBio Co Ltd's Net Income (Common)?
Net Income (Common)
-20.6B KRW

Based on the financial report for Dec 31, 2024, TiumBio Co Ltd's Net Income (Common) amounts to -20.6B KRW.

What is TiumBio Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-24%

Over the last year, the Net Income (Common) growth was -15%. The average annual Net Income (Common) growth rates for TiumBio Co Ltd have been 13% over the past three years , -24% over the past five years .

Back to Top